ES2906761T3 - Formulación líquida que comprende paeonol y apocinina - Google Patents

Formulación líquida que comprende paeonol y apocinina Download PDF

Info

Publication number
ES2906761T3
ES2906761T3 ES18810956T ES18810956T ES2906761T3 ES 2906761 T3 ES2906761 T3 ES 2906761T3 ES 18810956 T ES18810956 T ES 18810956T ES 18810956 T ES18810956 T ES 18810956T ES 2906761 T3 ES2906761 T3 ES 2906761T3
Authority
ES
Spain
Prior art keywords
apocynin
paeonol
isomer
formulation
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18810956T
Other languages
English (en)
Spanish (es)
Inventor
Nicholas John Larkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akl Research&development Ltd
Original Assignee
Akl Research&development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akl Research&development Ltd filed Critical Akl Research&development Ltd
Application granted granted Critical
Publication of ES2906761T3 publication Critical patent/ES2906761T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
ES18810956T 2017-11-23 2018-11-22 Formulación líquida que comprende paeonol y apocinina Active ES2906761T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1719464.8A GB2568698A (en) 2017-11-23 2017-11-23 Formulation
PCT/EP2018/082178 WO2019101842A1 (en) 2017-11-23 2018-11-22 Liquid formulation comprising paeonol and apocynin

Publications (1)

Publication Number Publication Date
ES2906761T3 true ES2906761T3 (es) 2022-04-20

Family

ID=60950758

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18810956T Active ES2906761T3 (es) 2017-11-23 2018-11-22 Formulación líquida que comprende paeonol y apocinina

Country Status (21)

Country Link
US (2) US11701325B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019005A1 (cg-RX-API-DMAC7.html)
JP (3) JP7314157B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250013306A (cg-RX-API-DMAC7.html)
CN (2) CN111372572B (cg-RX-API-DMAC7.html)
AU (2) AU2018371165B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082945A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124986T1 (cg-RX-API-DMAC7.html)
DK (1) DK3713546T3 (cg-RX-API-DMAC7.html)
ES (1) ES2906761T3 (cg-RX-API-DMAC7.html)
GB (1) GB2568698A (cg-RX-API-DMAC7.html)
HR (1) HRP20220303T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057595T2 (cg-RX-API-DMAC7.html)
LT (1) LT3713546T (cg-RX-API-DMAC7.html)
MX (2) MX393836B (cg-RX-API-DMAC7.html)
PL (1) PL3713546T3 (cg-RX-API-DMAC7.html)
PT (1) PT3713546T (cg-RX-API-DMAC7.html)
RS (1) RS62923B1 (cg-RX-API-DMAC7.html)
SI (1) SI3713546T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200101T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019101842A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2568698A (en) * 2017-11-23 2019-05-29 Akl Res & Development Ltd Formulation
GB202218160D0 (en) * 2022-12-02 2023-01-18 Akl Res & Development Ltd Formulation
CN119033608B (zh) * 2024-11-01 2025-03-25 深圳杉海创新技术有限公司 一种具有抑菌作用的低共熔溶剂、微脂囊及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920700613A (ko) * 1989-05-16 1992-08-10 지구르트 퓌터 약제제
CN100544708C (zh) * 2004-08-18 2009-09-30 上海佰加壹医药有限公司 一种丹皮酚软胶囊及其制备方法
GB2424833B (en) * 2005-04-08 2008-12-10 Nicholas John Larkins Anti-inflammatory formulation comprising apocyanin and paeonol
GB2463080A (en) * 2008-09-02 2010-03-03 Nicholas John Larkins Pharmaceutical preparation
GB201115757D0 (en) * 2011-09-12 2011-10-26 Akl Inflammatory Ltd Formulation for the treatment of benign prostate hyperplasia
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
GB2547241A (en) * 2016-02-11 2017-08-16 Akl Res & Dev Ltd Anti-inflammatory formulation
GB2568698A (en) * 2017-11-23 2019-05-29 Akl Res & Development Ltd Formulation

Also Published As

Publication number Publication date
NZ764238A (en) 2025-12-19
HRP20220303T1 (hr) 2022-05-13
CN116999417A (zh) 2023-11-07
CY1124986T1 (el) 2023-01-05
PT3713546T (pt) 2022-02-02
GB2568698A (en) 2019-05-29
MX2020005313A (es) 2020-08-17
GB201719464D0 (en) 2018-01-10
US20200297628A1 (en) 2020-09-24
LT3713546T (lt) 2022-03-10
JP2023104963A (ja) 2023-07-28
EP3713546B1 (en) 2021-12-08
KR20200090858A (ko) 2020-07-29
JP2025065531A (ja) 2025-04-17
CN111372572B (zh) 2023-08-29
CA3082945A1 (en) 2019-05-31
AU2018371165B2 (en) 2024-02-29
US20230330017A1 (en) 2023-10-19
CN111372572A (zh) 2020-07-03
MX2022008551A (es) 2022-08-10
JP2021504461A (ja) 2021-02-15
AU2024203514B2 (en) 2026-03-19
HUE057595T2 (hu) 2022-05-28
WO2019101842A1 (en) 2019-05-31
PL3713546T3 (pl) 2022-05-02
AU2024203514A1 (en) 2024-06-20
US11701325B2 (en) 2023-07-18
RS62923B1 (sr) 2022-03-31
SI3713546T1 (sl) 2022-04-29
SMT202200101T1 (it) 2022-03-21
EP3713546A1 (en) 2020-09-30
AU2018371165A1 (en) 2020-05-21
EP4019005A1 (en) 2022-06-29
KR102758107B1 (ko) 2025-01-20
DK3713546T3 (da) 2022-01-31
KR20250013306A (ko) 2025-01-31
JP7314157B2 (ja) 2023-07-25
MX393836B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
Aggarwal et al. Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements
JP6194400B2 (ja) 生薬等含有医薬組成物（弐）
AU2024203514B2 (en) Liquid formulation comprising paeonol and apocynin
ES2965739T3 (es) Solubilizado con curcumina y al menos otro principio activo
ES2230608T3 (es) Composicion farmaceutica destinada a una administracion por via oral.
BR112020006841A2 (pt) formulações de canabinoide sintéticas e à base de planta com ação prolongada e início rápido
ES2593858T3 (es) Método para preparar silibinina amorfa
ES2955586T3 (es) Composiciones que comprenden berberina
RU2708254C2 (ru) Пероральная композиция целекоксиба для лечения боли
US20150290268A1 (en) Formulations comprising herbal extracts
Saini et al. Synergistic effect of piperine and its derivatives: a comprehensive review
ES2215307T3 (es) Composiciones con accion sinergica para combatir selectivamente tejidos tumorales.
CN106176711B (zh) 包含类黄酮化合物组合物的药物及其应用
ES2353506T3 (es) Utilización de extractos de plantas del género sideritis para la prevención y/o el influjo sobre unos trastornos que están asociados con una neurotransmisión serotoninérgica modificada.
Ma et al. Volatile Oils from Natural Plants: Promising Penetration Enhancers for Biological Barriers
CN102861001B (zh) 桂皮醛治疗胃炎新用途
ES2861593B2 (es) Composicion farmaceutica que comprende una disolucion de silimarina en un solvente eutectico profundo de origen natural, metodos de obtencion y uso en medicina
ES2918021A1 (es) extracto de una planta de Marchantia y de polymorpha subsp. y sus usos
WO2016093680A1 (ru) Препарат на основе субстанции растительного происхождения, обладающий гепатопротекторным действием
BR102012005787A2 (pt) FORMULAÇÃO DA MISTURA DOS EXTRATOS HIDROALCÓOLICOS LIOFILIZADOS DAS FOLHAS DE AVERRHOA CARAMBOLA E DE SYZYGIUM CUMINI, SUAS COMPOSIÇÕES FARMACÊUTICAS E SEU USO NA PREVENÇÃO E NO TRATAMENTO DO DIABETES TIPO ii E SUAS COMPLICAÇÕES